Revisiting Pre-RAI MLR, PNI, and NRI Estimating Early and Higher Recurrence in Intermediate-Risk DTC in Thyroidology.

Authors

Ilker Sengul, Demet Sengul

Published in

Clinical endocrinology. Jul 27, 2026. Epub Jul 27, 2026.

Abstract

The therapeutic management of intermediate-risk differentiated thyroid carcinoma (DTC) remains a clinical conundrum, often caught between the Scylla of over-treatment and the Charybdis of disease persistence. While conventional risk stratification models predominantly emphasize histopathological and tumour-specific characteristics, the study by Piticchio et al. offers a salient contribution by shifting the focus towards the host's systemic immune landscape. By identifying the pre-radioiodine, RAI, Monocyte-to-Lymphocyte Ratio (MLR) as a robust, independent predictor of early recurrence, the authors provide a potentially transformative biomarker that enhances prognostic granularity beyond traditional staging. However, the interpretation of these haematological indices necessitates a nuanced understanding of the physiological milieu at the time of sampling. Specifically, the influence of profound iatrogenic hypothyroidism, induced by levothyroxine withdrawal, poses a significant confounding variable that may modulate circulating leucocyte dynamics independently of tumour biology. Furthermore, while the lack of prognostic utility for nutritional indices like the PNI and NRI underscores the preserved metabolic status of this cohort, it also invites a reassessment of whether more sensitive markers of body composition are required. This abstract evaluates the clinical implications of utilizing inflammatory ratios to refine postoperative surveillance and argues for the integration of host-immune interfaces into future oncological frameworks. Ultimately, while the MLR demonstrates significant potential for personalizing follow-up, prospective validation across diverse ethnic cohorts and under varying thyroid-stimulating hormone stimulation protocols is essential to establish its universal clinical utility.

PMID:
42504984
Bibliographic data and abstract were imported from PubMed on 27 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.